Chemotherapy combined with anti-HER2 and programmed cell death protein 1 (PD-1) blockade has become the standard first-line treatment for patients with HER2-positive gastric cancer and programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 1.5 This evidence concerns the gene ERBB2 and gastric cancer.